Compare ICICI Bank Limited Common Stock (IBN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ICICI Bank Limited Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? ICICI Bank Limited Common Stock trades at $28.61 (market cap $101.96B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: ICICI Bank Limited Common Stock is far larger — about 20.9× Travere Therapeutics Inc. Common Stock's market cap, and ICICI Bank Limited Common Stock pays a 0.88% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ICICI Bank Limited Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IBN | TVTX | |
|---|---|---|
Market Cap | $101.96B | $4.88B |
Volume | 5,301,480 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $32.94 | $67.52 |
52-Week Low | $25.20 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.90T | $5.01B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBN trades at $28.54, up 1.75% today, showing strong momentum with recent earnings beats in Q1 and Q2 2026. The stock maintains robust fundamentals including a 24.8% net income margin and 15.8% ROE, supported by $2.05T revenue in 2025. Technical indicators show bearish signals despite unanimous analyst buy ratings, with RSI suggesting potential overbought conditions near current levels.
The outlook remains positive given strong profitability metrics and analyst consensus, but technical weakness and high valuation multiples (P/E 17.85, P/S 4.43) present near-term risks. Investors should monitor Q3 2026 earnings results against expectations of $0.40 EPS for continued fundamental confirmation.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ICICI Bank Limited Common Stock
ICICI Bank is an Indian financial services company providing banking, lending, cards, insurance, and investment products. It serves retail, business, and corporate customers.
Read more on IBN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
